Following challenges with its drug candidate bexotegrast and announcement of a limited-duration stockholder rights program, ...

No Patient Left Behind says that drug value assessments used in countries like Canada and Germany undervalue innovative ...

As the Trump administration—including HHS Secretary Robert F. Kennedy Jr.—plays fast and loose with scientific studies and ...

Some 20 travel staff at the FDA, who made arrangements for the regulator’s inspectors, will be getting their jobs back, as ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

When it comes to vaccination, the COVID-19 pandemic divided American society. President Donald Trump and his new Health and ...

Global employee engagement fell two percentage points in 2024, according to Gallup, while BioSpace found that workforce ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.